Dysentry vaccine - Beijing Zhifei Lvzhu Biopharmaceutical
Alternative Names: S.flexneriza-S.sonnei bivalent conjugate vaccineLatest Information Update: 26 Feb 2025
At a glance
- Originator Beijing Zhifei Lvzhu Biopharmaceutical
- Class Antidiarrhoeals; Bacterial vaccines; Conjugate vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Dysentery
Most Recent Events
- 20 Feb 2025 Beijing Zhifei Lvzhu Biopharmaceutical plans a phase III trial for Dysentery (Prevention, In Infants, In children) in Bangladesh (IM) In April 2025 (NCT06838195)
- 11 Dec 2021 Phase-III clinical trials in Dysentery (In children, In infants, Prevention) in China (IM) (NCT05156528)
- 11 Dec 2021 Beijing Zhifei Lvzhu Biopharmaceutical plans a phase III trial for Dysentry in China (In infants, In children) (IM) (NCT05156528)